Login to Your Account

Acucela aims to raise $125M going public on Tokyo exchange

By Cornelia Zou
Staff Writer

Wednesday, January 15, 2014

HONG KONG – Looking to Japan for new funds, an embattled Seattle-based drug developer plans to issue shares on the Tokyo Stock Exchange in the hopes of raising as much as $125 million to develop ophthalmic treatments.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription